Foghorn Therapeutics (FHTX) Leases: 2020-2025
Historic Leases for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $10.2 million.
- Foghorn Therapeutics' Leases fell 57.71% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year decrease of 57.71%. This contributed to the annual value of $22.6 million for FY2024, which is 24.42% down from last year.
- According to the latest figures from Q3 2025, Foghorn Therapeutics' Leases is $10.2 million, which was down 6.40% from $10.9 million recorded in Q2 2025.
- Over the past 5 years, Foghorn Therapeutics' Leases peaked at $40.7 million during Q2 2021, and registered a low of $400,000 during Q1 2021.
- In the last 3 years, Foghorn Therapeutics' Leases had a median value of $25.5 million in 2024 and averaged $24.4 million.
- Its Leases has fluctuated over the past 5 years, first skyrocketed by 9,250.50% in 2022, then plummeted by 57.71% in 2025.
- Over the past 5 years, Foghorn Therapeutics' Leases (Quarterly) stood at $38.5 million in 2021, then dropped by 11.50% to $34.1 million in 2022, then declined by 12.12% to $30.0 million in 2023, then dropped by 24.42% to $22.6 million in 2024, then tumbled by 57.71% to $10.2 million in 2025.
- Its Leases was $10.2 million in Q3 2025, compared to $10.9 million in Q2 2025 and $21.2 million in Q1 2025.